HULUWA(SH:605199) Xin Lang Cai Jing·2025-08-29 16:32Core Viewpoint - ST Huhuwawa reported a significant decline in both revenue and profit for the first half of 2025, indicating financial distress and operational challenges [1][2]. Financial Performance - The company's revenue for the first half of 2025 was 508 million yuan, a year-on-year decrease of 42.89% [1]. - The net profit attributable to shareholders was 2.41 million yuan, down 94.14% year-on-year [1]. - The non-recurring net profit attributable to shareholders was -18.78 million yuan, a decline of 514.52% year-on-year [1]. - Basic earnings per share stood at 0.01 yuan [2]. Profitability Metrics - The gross profit margin for the first half of 2025 was 43.28%, down 8.06 percentage points year-on-year [2]. - The net profit margin was 0.89%, a decrease of 3.97 percentage points compared to the same period last year [2]. - In Q2 2025, the gross profit margin was 51.30%, down 2.46 percentage points year-on-year but up 12.09 percentage points quarter-on-quarter [2]. - The net profit margin for Q2 2025 was -11.69%, a decline of 15.19 percentage points year-on-year and down 18.96 percentage points from the previous quarter [2]. Expense Analysis - Total operating expenses for the first half of 2025 were 206 million yuan, a reduction of 225 million yuan year-on-year [2]. - The expense ratio was 40.67%, down 7.89 percentage points year-on-year [2]. - Sales expenses decreased by 60.25% year-on-year, while management expenses increased by 15.96% [2]. - R&D expenses fell by 80.69%, and financial expenses rose by 77.74% [2]. Shareholder Information - As of the end of the first half of 2025, the total number of shareholders was 31,600, a decrease of 11,900 or 27.30% from the previous quarter [2]. - The average market value of shares held per shareholder decreased from 136,400 yuan to 114,900 yuan, a decline of 15.76% [2]. Company Overview - ST Huhuwawa, established on June 22, 2005, is located in Haikou, Hainan Province, and was listed on July 10, 2020 [3]. - The company's main business includes the research, production, and sales of traditional Chinese medicine and chemical drugs [3]. - The revenue composition includes respiratory drugs (58.92%), digestive system drugs (21.43%), systemic anti-infection drugs (9.75%), other drugs (5.67%), and raw materials (4.22%) [3]. - The company belongs to the pharmaceutical and biological industry, specifically in the traditional Chinese medicine sector [3].